754235-62-6

Basic information

• Product Name: (5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER
• Synonyms: TIMTEC-BB SBB006830;(5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER;Ethyl (5-bromo-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)acetate;2-(5-bromo-2,3-diketo-indolin-1-yl)acetic acid ethyl ester;2-(5-bromo-2,3-dioxo-1-indolinyl)acetic acid ethyl ester;ethyl 2-(5-bromo-2,3-dioxoindol-1-yl)acetate;ethyl 2-(5-bromo-2,3-dioxo-indol-1-yl)ethanoate;ethyl 2-(5-bromo-2,3-dioxo-indolin-1-yl)acetate
• CAS NO: 754235-62-6
• Molecular Formula: C12H10BrNO4
• Molecular Weight: 312.12
• Mol File: 754235-62-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER(754235-62-6)
• EPA Substance Registry System: (5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER(754235-62-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 754235-62-6(Hazardous Substances Data)

Usage

Description

(5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER is a chemical compound with the molecular formula C11H11BrO4N and a molecular weight of 309.11 g/mol. It is an ester of acetic acid and is derived from the indole-2,3-dione structure. (5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER may have potential applications in the pharmaceutical industry, particularly in the development of new drugs and medications. Its specific properties and uses are still being researched and studied.

Uses

Used in Pharmaceutical Industry:
(5-BROMO-2,3-DIOXO-2,3-DIHYDRO-INDOL-1-YL)-ACETIC ACID ETHYL ESTER is used as a chemical compound for potential applications in the development of new drugs and medications. Its unique structure and properties are being investigated for their potential to contribute to pharmaceutical advancements.
Since the provided materials do not specify different applications in various industries, there is no need to list them separately. However, it is important to note that the compound's uses are still under research, and future findings may reveal additional applications in different industries.

Upstream product

• 2521-92-8 ethyl 2-((4-bromophenyl)amino)acetate 
• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 
• 19612-82-9 2-(2,3-dioxoindolin-1-yl)acetyl chloride 
• 41042-21-1 (1-ethoxycarbonylmethyl)isatin 

Downstream Products

• 1299028-15-1 C₁₂H₁₀BrCl₂NO₃ 
• 881608-39-5 ethyl (5-bromo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetate 

Relevant articles and documents

Development of potent nanosized isatin-isonicotinohydrazide hybrid for management of Mycobacterium tuberculosis

Inspired by the antitubercular activity of isoniazid (INH) and 5-bromoisatin, isatin–INH hybrid (WF-208) has been synthesized as a potent agent against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis. In silico molecular docking studies indicated that DprE1, a critical enzyme in the synthesis of M. tuberculosis cell wall, is a potential enzymatic target for WF-208. The synthesized WF-208 was incorporated into a nanoparticulate system to enhance stability of the compound and to sustain its antimicrobial effect. Nanosized spherical niosomes (hydrodynamic diameter of ca. 500–600 nm) could accommodate WF-208 at a high encapsulation efficiency of 74.2%, and could impart superior stability to the compound in simulated gastric conditions. Interestingly, WF-208 had minimal inhibitory concentrations (MICs) of 7.8 and 31.3 μg/mL against MDR and XDR M. tuberculosis, respectively, whereas INH failed to demonstrate bacterial growth inhibition at the range of the tested concentrations. WF-208-loaded niosomes exhibited a 4-fold increase in the anti-mycobacterial activity as compared to the free compound (MIC of 1.9 vs. 7.8 μg/mL) against H37Rv M. tuberculosis, after three weeks of incubation with WF-208-loaded niosomes. Incorporation of the compound into nanosized vesicles allowed for a further increase in stability, potency and sustainability of the anti-mycobacterial activity, thus, providing a promising strategy for management of tuberculosis.

CF 3 COOH/O 2 -Mediated Metal-Free Domino Construction of the Isatin Skeleton

Directed by the strategy of C-H activation, an efficient construction of the isatin skeleton was developed through aerobic oxidation of glycine esters. The reactions were performed under CF 3 COOH/O 2 conditions in the absence of met

SUBSTITUTED HETEROCYCLIC COMPOUNDS

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I) as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.